Combination Therapy for Palatable Food Intake Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are inadequate for addressing food addiction, obesity, binge eating disorder, and binge eating behavior, as they fail to effectively reduce intake of palatable foods and do not differentiate between standard and palatable food consumption.
Innovation Solution
A combination therapy using a mu-opioid receptor antagonist and a GABA B receptor agonist, optionally with additional therapeutic agents such as CB-1 receptor antagonists or dopamine augmenting compounds, to specifically target and reduce the intake of palatable foods like those high in sugar and fat, while leaving standard chow intake unaffected.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current treatments are used for food addiction and obesity, then general food intake may be reduced, but palatable food intake is not effectively reduced and standard food consumption is also affected
Solution Approach 1:
The combination therapy targets specific neural pathways (mu-opioid and GABA B receptors) that are selectively involved in palatable food consumption rather than general food intake. This allows the treatment to differentially affect palatable versus standard food consumption by acting on specific local neural circuits rather than global appetite control mechanisms.
Solution Approach 2:
Instead of trying to increase satiety or reduce hunger signals globally, the invention inverts the approach by directly blocking the reward and reinforcement pathways that specifically drive palatable food seeking and consumption. The mu-opioid antagonist and GABA B agonist work together to inhibit the hedonic aspects of eating without affecting homeostatic hunger-satiety mechanisms.
2Reliability
If a combination therapy with multiple therapeutic agents is used, then the effectiveness in reducing caloric intake from palatable sources is enhanced, but the complexity of the treatment regimen increases
Solution Approach 1:
The invention combines a mu-opioid receptor antagonist and a GABA B receptor agonist into a coordinated treatment regimen. These two agents work synergistically by targeting complementary aspects of the reward pathway: the antagonist blocks opioid-mediated pleasure from palatable food, while the agonist enhances GABAergic inhibition of food-seeking behavior. This merging of mechanisms produces greater effectiveness than either agent alone.
Solution Approach 2:
The combination therapy addresses multiple aspects of food addiction simultaneously: craving reduction, impulse control, and reward sensitivity. By targeting both mu-opioid and GABA B receptors, the treatment provides multi-functional effects that cover various dimensions of compulsive eating behavior, making it applicable to diverse presentations of food addiction and binge eating disorder.
Data Source
AI summary
The present invention is directed to a combination treatment for: individuals who meet the definition of food addiction; individuals who are overweight or obese (e.g., a BMI≧25); individuals who have a binge eating disorder; or individuals who engage in a binge eating behavior. In particular embodiments, the combination therapy reduces the intake of fatty foods, sugar-rich foods, or foods that are both fatty and sugar-rich (e.g., fast foods).